OptiBiotix Plc

H2 Summary

By Mike Caine | 2nd October 2023

I have an investment in OptiBiotix Health.

Previously writing on OptiBiotix back in July at a 20.8p share price, and following our sometimes-scathing summary of the communication tactics employed by the Directors, we did note an apparent change in outlook and surprisingly to many, I put OptiBiotix back on my watchlist pending further announcements. I did sound the alarm bell that the update on the 19th of July was only an RCS (which propelled the share price 150%) and that little, if any, of the information supplied in that RCS was included in the audited RNS of the 29th of August. The very important but obvious question is, why not? We now have an agreement, someway off still, with Boots.....

On to the recent Half-year Report issued on the 27th September. Much excellent content was given in an article by Alex a few days ago, so I do not intend to repeat the same figures. Whilst growth figures look exceptional, the Sales and Revenues are low, very low. I am sure we can all recall the promises that each agreement would be worth at least £500k and as much as £1.5m per annum (we had 70+ at one point). I also ask at what point overheads (staff costs) will have to be increased again to meet or sustain growth.